Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | TLR4 | O00206 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13235182 | 1.00 | OPRM1 (0.32) | OPRM1OPRK1OPRL1TLR4PDK2 | |
| SCHEMBL2892557 | 0.93 | OPRM1 (0.33) | OPRM1OPRK1OPRL1PDK2SSTR5 | |
| SCHEMBL13378062 | 0.93 | OPRM1 (0.33) | OPRM1OPRK1OPRL1PDK2SSTR5 | |
| SCHEMBL2892563 | 0.93 | OPRM1 (0.33) | OPRM1OPRK1OPRL1PDK2SSTR5 | |
| SCHEMBL13235177 | 0.92 | OPRM1 (0.32) | OPRM1OPRK1OPRL1PDK2 | |
| SCHEMBL2882773 | 0.92 | OPRM1 (0.32) | OPRM1OPRK1OPRL1PDK2 | |
| SCHEMBL9979284 | 0.87 | TLR4 (0.32) | OPRM1OPRK1OPRL1TLR4 | |
| SCHEMBL2931710 | 0.84 | S1PR5 (0.34) | OPRM1OPRK1OPRL1PDK2 | |
| SCHEMBL20808415 | 0.81 | OPRM1 (0.35) | OPRM1OPRK1OPRL1TLR4 | |
| SCHEMBL20808413 | 0.81 | OPRM1 (0.35) | OPRM1OPRK1OPRL1TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1873134-B1 | CHLOROFLUOROBENZENE LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORP (JP) | 2013-02-13 | — | — | EP | disclosed |
| US-7758931-B2 | Chlorofluorobenzene liquid crystal compound, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2010-07-20 | — | — | US | disclosed |
| US-20090264683-A1 | CHLOROFLUOROBENZENE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2009-10-22 | — | — | US | disclosed |
| US-7569258-B2 | Chlorofluorobenzene liquid crystal compound, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20060198968-A1 | cyclohexenylene compounds which have a phenylene ring both fluoro and chloro substituted; wide temperature range; heat and light stable; small viscosity, large optical anisotropy; suitable negative dielectric anisotropy and excellent compatibility with other liquid crystal compounds; short response times | JIANGSU HECHENG DISPLAY TECHNOLOGY CO., LTD. (CN) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264683-A1 | CHLOROFLUOROBENZENE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CCND3, CCND1, SLFN12 | OPRM1 4071/4885OPRK1 2190/4885OPRL1 3629/4885 |
| US-20060198968-A1 | cyclohexenylene compounds which have a phenylene ring both fluoro and chloro substituted; wide temperature range; heat and light stable; small viscosity, large optical anisotropy; suitable negative dielectric anisotropy and excellent compatibility with other liquid crystal compounds; short response times | CCND3, CCND1, TCF12 | OPRM1 3875/4885OPRK1 1818/4885OPRL1 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.